immunotherapy

What Makes Some Kidney Cancers Resistant to Immunotherapy?

What Makes Some Kidney Cancers Resistant to Immunotherapy?

Posted by  | Research

Suzanne Topalian, M.D., associate director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy, is a pioneer in the search for biomarkers that predict responses to immunotherapy. In April at the American Association for Cancer Research meeting in New Orleans, Topalian and her colleagues presented data linking a virus-associated cancer, called Merkel cell carcinoma - to response(...)

Study: First Hints that Anti-PD-1 Therapy May Help Men with Advanced Prostate Cancer

Study: First Hints that Anti-PD-1 Therapy May Help Men with Advanced Prostate Cancer

Posted by  | Research

So-called anti-PD-1 drugs, which block the interaction between proteins on cancer and immune cells, are currently approved by the Food and Drug Administration for certain patients with melanoma and non-small cell lung, kidney and bladder cancers. Now, a new study led by scientists at Oregon Health & Science University's Knight Cancer Institute and partially funded(...)

Celebrating the End of Cancer Treatment

Celebrating the End of Cancer Treatment

Posted by  | Patient Stories

Stefanie Joho, 25, had been given a death sentence. Diagnosed with advanced colon cancer, she traveled to cancer centers around the U.S. in search of a therapy that could buy her time. She found it at the Johns Hopkins Kimmel Cancer Center -- the result of a combination of recent scientific advances in immunotherapy and(...)

Side effects of immunotherapy: what to look for and when?

Side effects of immunotherapy: what to look for and when?

Posted by  | treatment

Julie Brahmer, M.D., director of the Thoracic Oncology Program, began treating patients with immunotherapy drugs nearly a decade ago. She led one of the first large studies of the popular drugs, which was reported in 2012. Since then, Brahmer, a program leader in the Bloomberg-Kimmel Institute for Cancer Immunotherapy, has become an expert in identifying(...)

Can biomarkers predict patients’ response to immunotherapy?

Posted by  | Research

Immunotherapy expert, Suzanne Topalian, M.D., delivered a presentation to a standing room only crowd at the 2016 American Society of Clinical Oncology (#ASCO16) regarding new directions in scientists’ search for biomarkers that identify patients and tumor types most likely to respond to immunotherapy drugs. Among the approaches is an immunohistochemistry test for the protein PD-L1,(...)

One-third of patients with metastatic melanoma treated with immunotherapy drug nivolumab survive five years

Posted by  | Research

At the 2016 American Association for Cancer Research annual meeting today, scientists presented their results of a follow-up study tracking the survival of metastatic melanoma patients who were treated with the immunotherapy drug nivolumab. The drug is currently approved by the U.S. Food and Drug Administration for advanced lung and kidney cancers and advanced melanomas.(...)

Vice President Biden Speaks at Launch of Bloomberg~Kimmel Institute for Cancer Immunotherapy

Posted by  | Uncategorized

Vice President Joe Biden spoke to researchers, medical students, government leaders and others during the dedication of the new Bloomberg~Kimmel Institute for Cancer Immunotherapy. It was founded with gifts of $50 million each from Michael R. Bloomberg and Sidney Kimmel, and $25 million from more than a dozen additional supporters. Read the immunotherapy feature story(...)

A Conversation about Cancer

A Conversation about Cancer

Posted by  | precision medicine, Prevention/Screening, Research, Uncategorized

On Nov. 3, 2015, a capacity crowd of more than 250 Johns Hopkins leaders, faculty, staff, students, donors, and other guests filled the Albert H. Owens Auditorium at the Johns Hopkins Kimmel Cancer Center to honor the philanthropy of Sidney Kimmel for advancing cancer discovery and care. Hundreds more watched via video streaming as Kimmel(...)

Immunotherapy drug approved for lung cancer

Posted by  | treatment

There is good news today for lung cancer patients. The FDA has announced that it has approved expansion of the immunotherapy drug nivolumab (Opdivo) for certain lung cancer patients. Julie Brahmer, M.D., oncologist at the Johns Hopkins Kimmel Cancer Center and director of its Thoracic Oncology Program, is one of the leaders of the initial,(...)